UroGen Pharma's Losses Widen Amid Soaring Expenses, Cash Drains

TL;DR

**URGN is burning cash at an alarming rate, and while Zusduri's approval is a win, the path to profitability looks long and expensive.**

AI Summary

UroGen Pharma Ltd. reported a significant increase in net loss for the nine months ended September 30, 2025, reaching $127.1 million, up from $89.4 million in the same period of 2024. This 42.2% increase in net loss occurred despite a 9.3% rise in revenue to $71.95 million from $65.83 million. The company's operating loss widened to $105.7 million for the nine months, compared to $69.1 million in the prior year, driven by substantial increases in operating expenses. Research and development expenses climbed to $52.79 million from $42.25 million, a 25% increase, while selling, general and administrative expenses surged by 34.1% to $115.75 million from $86.30 million. Cash and cash equivalents decreased significantly to $90.04 million as of September 30, 2025, from $171.99 million at December 31, 2024, reflecting substantial cash used in operating activities, totaling $124.1 million. The FDA approval of Zusduri on June 12, 2025, for recurrent low-grade intermediate risk non-muscle invasive bladder cancer, represents a key business change, alongside the continued commercialization of Jelmyto. The company acknowledges an accumulated deficit of $933.4 million and expects continued losses, with its ability to continue as a going concern dependent on product sales and future capital raises.

Why It Matters

UroGen Pharma's widening net loss and significant cash burn are critical for investors, signaling increased financial pressure despite revenue growth. The successful FDA approval of Zusduri offers a potential new revenue stream, but its commercialization costs are clearly impacting the bottom line, as evidenced by the 34.1% jump in SG&A expenses. This competitive landscape in urothelial cancer treatments means UroGen must rapidly scale sales of both Jelmyto and Zusduri to achieve profitability. Employees face uncertainty if the company struggles to secure additional financing, while customers could benefit from new non-surgical treatment options if UroGen can sustain its operations.

Risk Assessment

Risk Level: high — UroGen Pharma reported an accumulated deficit of $933.4 million as of September 30, 2025, and a net loss of $127.1 million for the nine months ended September 30, 2025. Cash and cash equivalents plummeted from $171.99 million at December 31, 2024, to $90.04 million at September 30, 2025, with $124.1 million used in operating activities, indicating a substantial cash drain and significant going concern risk.

Analyst Insight

Investors should exercise extreme caution and consider reducing exposure to URGN given the accelerating net losses and significant cash burn. Monitor the commercial uptake of Zusduri closely, as its success is crucial for future revenue generation and mitigating the need for further dilutive financing rounds.

Financial Highlights

debt To Equity

N/A

revenue

$71.95M

operating Margin

N/A

total Assets

$185.05M

total Debt

$122.11M

net Income

$ -127.1M

eps

N/A

gross Margin

N/A

cash Position

$90.04M

revenue Growth

+9.3%

Revenue Breakdown

Key Numbers

• $127.1M — Net Loss (for the nine months ended September 30, 2025, up from $89.4M in 2024)
• $71.95M — Revenue (for the nine months ended September 30, 2025, up from $65.83M in 2024)
• $105.7M — Operating Loss (for the nine months ended September 30, 2025, widened from $69.1M in 2024)
• $52.79M — Research and Development Expenses (for the nine months ended September 30, 2025, up from $42.25M in 2024)
• $115.75M — Selling, General and Administrative Expenses (for the nine months ended September 30, 2025, up from $86.30M in 2024)
• $90.04M — Cash and Cash Equivalents (as of September 30, 2025, down from $171.99M at December 31, 2024)
• $124.1M — Net Cash Used in Operating Activities (for the nine months ended September 30, 2025)
• $933.4M — Accumulated Deficit (as of September 30, 2025)

Key Players & Entities

• UroGen Pharma Ltd. (company) — registrant
• UroGen Pharma, Inc. (company) — wholly owned subsidiary
• FDA (regulator) — approved Jelmyto and Zusduri
• Jelmyto (company) — commercial product for low-grade UTUC
• Zusduri (company) — FDA-approved medication for low-grade intermediate risk NMIBC
• Nasdaq Stock Market LLC (company) — exchange where URGN is registered
• Bloomberg (company) — publisher
• SEC (regulator) — filing oversight

FAQ

Risk Factors

• Going Concern Uncertainty [high — financial]: The company has an accumulated deficit of $933.4 million and experienced a net loss of $127.1 million for the nine months ended September 30, 2025. Its ability to continue as a going concern is dependent on future product sales and the successful raising of additional capital.
• Increasing Operating Expenses [high — operational]: Operating expenses surged, with R&D up 25% to $52.79 million and SG&A up 34.1% to $115.75 million for the nine months ended September 30, 2025. This significant increase in costs outpaced revenue growth, widening the operating loss.
• FDA Approval Dependence [medium — regulatory]: The company's growth strategy relies heavily on FDA approvals, such as the recent approval of Zusduri. Delays or failures in obtaining regulatory approvals for future products could significantly impact financial performance.
• Declining Cash Reserves [high — financial]: Cash and cash equivalents decreased by $81.95 million to $90.04 million as of September 30, 2025, from $171.99 million at December 31, 2024, primarily due to $124.1 million in net cash used in operating activities.

Industry Context

UroGen Pharma operates in the oncology sector, specifically focusing on urothelial cancers. The market for bladder cancer treatments is competitive, with ongoing development of novel therapies. Key trends include the shift towards targeted therapies and immunotherapies, as well as the importance of regulatory approvals for market access.

Regulatory Implications

The company's reliance on FDA approvals for its product pipeline, such as Zusduri, presents significant regulatory risk. Any delays or rejections in the approval process could severely impact revenue projections and future growth. Compliance with stringent pharmaceutical regulations is paramount.

What Investors Should Do

1. [object Object]
2. [object Object]
3. [object Object]

Key Dates

• 2025-06-12: FDA approval of Zusduri — Represents a key new product approval, potentially expanding the company's revenue streams and market reach in bladder cancer treatment.
• 2025-09-30: End of Q3 2025 — Reporting period for the 10-Q, showing a significant increase in net loss and a substantial decrease in cash reserves.
• 2024-09-30: End of Q3 2024 — Prior year comparable period for financial results, showing a lower net loss and higher cash position.
• 2024-12-31: End of Fiscal Year 2024 — Previous year-end balance sheet figures, providing a baseline for the significant decrease in cash and cash equivalents.

Glossary

Accumulated Deficit

The cumulative net losses of a company that have not been offset by net income or other gains since its inception. (Indicates the company has historically incurred more expenses than revenues, totaling $933.4 million as of September 30, 2025.)

Going Concern

An accounting assumption that a business will continue to operate for the foreseeable future. (The company's financial condition raises doubts about its ability to continue as a going concern without additional funding.)

Research and Development Expenses (R&D)

Costs incurred by a company in the process of developing new products or services, or improving existing ones. (UroGen's R&D expenses increased by 25% to $52.79 million for the nine months ended September 30, 2025, indicating significant investment in future products.)

Selling, General and Administrative Expenses (SG&A)

Costs associated with marketing, advertising, sales, and general overhead of a company. (SG&A expenses rose by 34.1% to $115.75 million for the nine months ended September 30, 2025, a major driver of the increased operating loss.)

Year-Over-Year Comparison

Compared to the prior year's nine-month period, UroGen Pharma reported a 9.3% increase in revenue to $71.95 million. However, this revenue growth was overshadowed by a significant 42.2% increase in net loss to $127.1 million. Operating expenses, particularly R&D and SG&A, saw substantial increases of 25% and 34.1% respectively, leading to a wider operating loss. Cash reserves have also diminished considerably, falling from $171.99 million at the end of 2024 to $90.04 million by September 30, 2025, highlighting increased cash burn.

Filing Documents

• urgn20250930_10q.htm (10-Q) — 1965KB
• ex_880854.htm (EX-10.1) — 27KB
• ex_856485.htm (EX-31.1) — 17KB
• ex_856486.htm (EX-31.2) — 17KB
• ex_856487.htm (EX-32.1) — 6KB
• ex_856488.htm (EX-32.2) — 6KB
• ex_880854img001.jpg (GRAPHIC) — 1KB
• ex_880854img002.jpg (GRAPHIC) — 1KB
• ex_880854img003.jpg (GRAPHIC) — 1KB
• 0001437749-25-033468.txt ( ) — 8615KB
• urgn-20250930.xsd (EX-101.SCH) — 80KB
• urgn-20250930_cal.xml (EX-101.CAL) — 57KB
• urgn-20250930_def.xml (EX-101.DEF) — 482KB
• urgn-20250930_lab.xml (EX-101.LAB) — 431KB
• urgn-20250930_pre.xml (EX-101.PRE) — 529KB
• urgn20250930_10q_htm.xml (XML) — 1300KB

Financial Statements (Unaudited)

Financial Statements (Unaudited) 1 Condensed Consolidated Balance Sheets 1 Condensed Consolidated Statements of Operations and Comprehensive Loss 2 Condensed Consolidated Statements of Shareholders ' Deficit 3 Condensed Consolidated Statements of Cash Flows 5 Notes to Unaudited Condensed Consolidated Financial Statements 6 Item 2. Management ' s Discussion and Analysis of Financial Condition and Results of Operations 24 Item 3.

Quantitative and Qualitative Disclosures About Market Risk

Quantitative and Qualitative Disclosures About Market Risk 36 Item 4.

Controls and Procedures

Controls and Procedures 38 PART II. OTHER INFORMATION 39 Item 1.

Legal Proceedings

Legal Proceedings 39 Item 1A.

Risk Factors

Risk Factors 39 Item 2. Unregistered Sales of Equity Securities and Use of Proceeds 87 Item 3. Defaults Upon Senior Securities 87 Item 4. Mine Safety Disclosures 87 Item 5. Other Information 87 Item 6. Exhibits 88

Signatures

Signatures 89 Trademarks and Trade Names Unless the context requires otherwise, references in this Quarterly Report to the "Company," "UroGen," "we," "us" and "our" refer to UroGen Pharma Ltd. and its subsidiary, UroGen Pharma, Inc. UroGen , RTGel , Jelmyto and Zusduri are trademarks of ours that we use in this Quarterly Report. This Quarterly Report also includes trademarks, tradenames, and service marks that are the property of other organizations. Solely for convenience, our trademarks and tradenames referred to in this Quarterly Report appear without the or symbols, but those references are not intended to indicate, in any way, that we will not assert, to the fullest extent under applicable law, our rights, or the right of the applicable licensor to our trademark and tradenames. We do not intend our use or display of other companies' trade names or trademarks to imply a relationship with, or endorsement or sponsorship of us by, any other companies. i Table of Contents

— Financial Information

Part I — Financial Information

Financial Statements

Item 1. Financial Statements. UroGen Pharma Ltd. Condensed Consolidated Balance Sheets (unaudited; in thousands, except share amounts and par value) September 30, December 31, 2025 2024 Assets Current assets: Cash and cash equivalents $ 90,039 $ 171,987 Marketable securities 36,994 64,698 Restricted cash 1,347 1,076 Accounts receivable, net 19,703 20,302 Inventories 8,341 9,227 Prepaid expenses and other current assets 12,122 8,845 Total current assets 168,546 276,135 Non-current assets: Property and equipment, net 695 655 Restricted deposit 177 176 Right of use assets 8,489 3,134 Marketable securities 380 5,022 Other non-current assets 6,759 589 Total Assets $ 185,046 $ 285,711 Liabilities and Shareholders' Deficit Current liabilities: Accounts payable and accrued expenses $ 26,173 $ 27,431 Employee related accrued expenses 11,114 10,570 Other current liabilities 4,957 7,948 Total current liabilities: 42,244 45,949 Non-current liabilities: Prepaid forward obligation 126,067 121,387 Long-term debt 122,111 121,734 Long-term lease liabilities 6,241 1,653 Uncertain tax positions liability 3,791 3,791 Total Liabilities 300,454 294,514 Commitments and Contingencies (Note 19) Shareholders' Deficit: Ordinary shares, NIS 0.01 par value, 100,000,000 shares authorized at September 30, 2025 and December 31, 2024; 46,781,211 and 42,231,746 shares issued and outstanding as of September 30, 2025 and December 31, 2024, respectively 128 115 Additional paid-in capital 817,793 797,248 Accumulated deficit ( 933,352 ) ( 806,222 ) Accumulated other comprehensive income 23 56 Total Shareholders' Deficit ( 115,408 ) ( 8,803 ) Total Liabilities and Shareholders' Deficit $ 185,046 $ 285,711 The accompanying notes are an integral part of these condensed consolidated financial statements. 1 Table of Contents UroGen Pharma Ltd. Condensed Consolidated Statements of Operations and Co